Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | USP5 | P45974 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | GIPR | P48546 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13749330 | 0.91 | GCGR (0.44) | MEN1KMT2ACNR1ALDH1A1USP5 | |
| SCHEMBL2251590 | 0.91 | KMT2A (0.48) | MEN1KMT2AGAACNR1ALDH1A1 | |
| SCHEMBL2667291 | 0.88 | GCGR (0.59) | USP5GCGRGIPR | |
| SCHEMBL2253874 | 0.84 | GCGR (0.42) | MEN1KMT2AALDH1A1USP5GCGR | |
| SCHEMBL2667296 | 0.84 | GCGR (0.57) | GAAALDH1A1GCGRGIPR | |
| SCHEMBL4271083 | 0.83 | PSEN1 (0.45) | GAAALDH1A1POLBGCGRGIPR | |
| SCHEMBL13003304 | 0.83 | GCGR (0.53) | USP5GCGRGIPR | |
| SCHEMBL2250281 | 0.80 | GCGR (0.43) | MEN1KMT2ACNR1GCGRGIPR | |
| SCHEMBL2251290 | 0.80 | GCGR (0.45) | MEN1KMT2AGCGRGIPR | |
| SCHEMBL2667300 | 0.80 | GCGR (0.58) | USP5GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989475-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1590336-B1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090215825-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215825-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GLP1R, GCGR, GPR119 | MEN1 2999/4885KMT2A 3734/4885GAA 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.